Edition:
United States

Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

12.09USD
23 Sep 2016
Change (% chg)

$-0.31 (-2.50%)
Prev Close
$12.40
Open
$12.38
Day's High
$12.45
Day's Low
$12.08
Volume
379,552
Avg. Vol
385,800
52-wk High
$18.65
52-wk Low
$6.96

HALO.OQ

Chart for HALO.OQ

About

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborat... (more)

Overall

Beta: 2.21
Market Cap(Mil.): $1,564.62
Shares Outstanding(Mil.): 129.41
Dividend: --
Yield (%): --

Financials

  HALO.OQ Industry Sector
P/E (TTM): -- 42.52 36.60
EPS (TTM): -0.52 -- --
ROI: -33.73 -0.26 13.91
ROE: -222.22 -3.05 14.82

BRIEF-Halozyme reports second quarter 2016 financial results

* Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

Aug 09 2016

BRIEF-Halozyme to resume enrollment in Phase 1B trial evaluating PEGPH20

* Resumed enrollment, dosing patients in phase 1B trial evaluating investigational new drug, PEGPH20, in combination with KEYTRUDA

Jul 25 2016

BRIEF-Halozyme announces agreement to refinance debt

* Entered into agreement with Oxford Finance Llc and Silicon Valley Bank to refinance its existing senior secured loan facility

Jun 08 2016

BRIEF-Halozyme Q1 loss per share $0.16

* Halozyme therapeutics inc sees 2016 net revenues to be in range of $130 million to $145 million

May 09 2016

BRIEF-Halozyme Therapeutics expands oncology pipeline with two compounds designed for activity in tumor microenvironment

* Says halozyme expands oncology pipeline with two compounds designed for activity in tumor microenvironment Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Apr 18 2016

Competitors

  Price Chg
Novo Nordisk A/S (NOVOb.CO) kr.296.80 -7.20
Sanofi SA (SASY.PA) €68.45 -0.48
Eli Lilly and Co (LLY.N) $81.16 -0.13
Biodel Inc (BIOD.OQ) $0.45 +0.03
MannKind Corporation (MNKD.OQ) $0.61 -0.07

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$127.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.